Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 37 versus OLINVYK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 37 versus OLINVYK.
DURAGESIC-37 vs OLINVYK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl binds to mu-opioid receptors, activating G-protein coupled receptor signaling, leading to inhibition of adenylate cyclase, decreased cAMP production, and modulation of ion channels (increased potassium efflux, decreased calcium influx). This results in reduced neuronal excitability, inhibition of nociceptive transmission, and altered pain perception. Additionally, fentanyl may interact with other opioid receptors (kappa, delta) with lower affinity.
Oliceridine is a G protein-biased μ-opioid receptor agonist. It preferentially activates the G protein pathway (associated with analgesia) over β-arrestin recruitment (associated with opioid-related adverse effects like respiratory depression and gastrointestinal dysfunction).
Initial: 25 mcg/hour transdermal patch applied every 72 hours. Titrate based on opioid tolerance. For opioid-naive patients: 12 mcg/hour patch.
Initial adult dose: 1.5 mg intravenously (IV) every 3 to 6 hours as needed. May be titrated in increments of 0.75 mg to 1.5 mg every 3 to 6 hours. Maximum single dose: 4.5 mg. Maximum daily dose: 27 mg.
None Documented
None Documented
Terminal elimination half-life 20-27 hours (range 13-42 h) after transdermal removal; due to continuous absorption from skin depot, effective half-life is longer during patch wear.
Terminal elimination half-life is approximately 26–29 hours, supporting once-daily dosing in chronic pain
Primarily renal: 75% as metabolites (mostly norfentanyl) and <10% unchanged drug. Fecal: 9% via biliary elimination.
Primarily renal (approximately 90% as unchanged drug and metabolites); biliary/fecal excretion accounts for <5%
Category C
Category C
Opioid Analgesic
Opioid Analgesic